Australia: The Sansom Review: Streamlining the approval and advertising of therapeutic goods in Australia

After a two-year review process, the Australian Government has committed to enacting the recommendations of the Sansom Review, which will create a more streamlined and efficient system for the regulation of therapeutic goods in Australia.

The Government expects that the implementation of the recommendations (which are summarised below) will deliver significant benefits to the Australian public and to the Australian medicine and medical device industries.

ABOUT THE SANSOM REVIEW

In 2014, the Department of Health announced an independent review of medicines and medicinal devices regulation by Emeritus Professor Lloyd Sansom AO, Will Delaat AM and Professor John Horvath AO. Two reports on the review were delivered by the expert panel in March and July 2015 making 58 recommendations for reform of the regulation of medicines and medical devices in Australia (together known as the Sansom Review).

On 15 September 2016, the Australian Government released a response to the Sansom Review, and accepted 56 of 58 recommendations made by the review. These recommendations will be implemented in a staged approach over the next three years to limit disruption to industry. The Government has begun the implementation process by opening a series of industry consultations, which invite stakeholders to provide input on how the more complex Sansom Review recommendations should be implemented.

THE TOP 4 RECOMMENDATIONS OF THE SANSOM REVIEW

  1. Workshare arrangements with overseas authorities

The Sansom Review recommended an overhaul of the registration system for new chemical entities, generic medicines, biosimilars and medical devices so that the review process could effectively be shared between the Therapeutic Goods Administration (TGA) and its overseas counterparts.

Under these recommendations, when a sponsor applies for registration of a new drug, rather than submitting a full application specifically for the Australian market, it can submit an evaluation report from a comparable overseas authority, such as the US Food and Drug Administration, along with an abbreviated Australian application. The TGA is currently seeking submissions from stakeholders regarding the criteria it will use to identify comparable overseas regulators.

The Sansom Review also suggested that the TGA engage in work-sharing arrangements with comparable overseas drug authorities to make the approval process faster and more efficient.

This new process could result in a decrease to the application and evaluation fees payable by sponsors. As of 1 July 2016, the total application and evaluation fees for a 'new chemical entity' in Australia was $231,200 – a reduction in these fees may encourage innovation from smaller market participants.

  1. A "fast track" application process

Another significant recommendation made by the Sansom Review was to introduce an accelerated review stream. Although the circumstances under which products will be eligible for this expedited review are not clear from the Sansom Review – it aims to give patients faster access to cutting edge treatments.

  1. Incentives for innovation in complementary medicines

The Sansom Review acknowledged that the current regulatory framework does not adequately incentivise innovation in complementary medicines.

As it stands, sponsors have little incentive to invest in research and development of complementary medicines, as they are not granted any form of market exclusivity period to recoup the R&D investment.

Although the Sansom Review concluded that it was 'outside its terms of reference' to make more specific recommendations on this point, it hinted that the data protection period available for some registered medicines could be extended to all complementary medicines as a mechanism to drive innovation.

Several other interesting recommendations were made in relation to complementary medicines, including:

  • where the product is listed on the Australian Register of Therapeutic Goods (the ARTG), the sponsor be required to publish on a website the evidence that it holds to support all the indications included on the ARTG entry (while supporting the intent of this recommendation, the Government will not require but will encourage self-publishing);
  • where the product is listed on the ARTG through the self-assessment route, the sponsor be required to include a prominent disclaimer on promotional materials to the effect that the efficacy claims have not been independently assessed (the Government support the intent of this recommendation but noted that further consultation was required); and
  • where the product is listed on the ARTG through TGA assessment, the sponsor is able to indicate on promotional materials that the efficacy of a product has been independently assessed (the Government accepted this recommendation in principle, noting that the permitted promotional statements will require further consideration).
  1. Streamlined advertising regulation

The Sansom Review proposed a more streamlined system for advertising and specifically recommended that:

  • the vetting and pre-approval process for advertising should be scrapped and the industry should move to a self-regulation model;
  • all advertising complaints should be dealt with by the same body (the TGA is currently seeking stakeholder input on how this body should operate);
  • future advertising regulation should be consistent for all medicines and medical devices; and
  • the TGA should facilitate the development of sponsor educational programs and resources about therapeutic goods advertising.

THE AUSTRALIAN GOVERNMENT'S RESPONSE TO THE SANSOM REVIEW

The Australian Government accepted 56 out of the 58 recommendations in the Sansom Review.



The implementation of these changes will result in significant changes to the regulation of therapeutic goods in Australia. This reflects the Government's desire, through the National Innovation and Science Agenda and the Industry, Innovation and Competitiveness Agenda, to boost competitiveness and innovation and lessen unnecessary regulatory burden.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Chambers Asia Pacific Awards 2016 Winner – Australia
Client Service Award
Employer of Choice for Gender Equality (WGEA)

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions